News

Vienna to Host RARE2019 Meeting on Rare Diseases

About 100 scientists, researchers, pharmaceutical executives, and others will converge on Austria’s capital city early next month for the 2nd International Congress on Advanced Treatments in Rare Diseases. The March 4-5 meeting, to take place at the Hilton Am Stadtpark Vienna, features 27 speakers on a variety of disorders…

Molecular Analysis Pinpoints Potentially Important Pathways for Classical EDS

A gene expression analysis identified several deregulated pathways in fibroblasts from classical Ehlers-Danlos syndrome (EDS) patients, offering new insights for future studies investigating the disease mechanisms and potential therapies, a study reports. The study, “Molecular insights in the pathogenesis of classical Ehlers-Danlos syndrome from transcriptome-wide expression profiling of…

Excellagen, a Potential Treatment for EDS, is Poised for Launch

Generex Biotechnology will launch a wound care gel formulation called Excellagen, a potential treatment option for patients with Ehlers-Danlos syndrome (EDS) among others disorders. Excellagen is a highly-purified type 1 collagen-based, topical gel. According to Generex, its 3D dermal matrix favors wound healing. It activates platelets, leading to the…

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…